Forsta AP Fonden Decreases Stock Holdings in Edwards Lifesciences Corporation $EW

Forsta AP Fonden lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 0.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 121,300 shares of the medical research company’s stock after selling 900 shares during the period. Forsta AP Fonden’s holdings in Edwards Lifesciences were worth $9,487,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth about $266,000. CWM LLC grew its stake in shares of Edwards Lifesciences by 36.3% in the first quarter. CWM LLC now owns 32,916 shares of the medical research company’s stock valued at $2,386,000 after buying an additional 8,772 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Edwards Lifesciences by 11.5% during the 1st quarter. Signaturefd LLC now owns 6,202 shares of the medical research company’s stock valued at $450,000 after buying an additional 638 shares during the period. Sigma Planning Corp raised its holdings in shares of Edwards Lifesciences by 4.9% during the 1st quarter. Sigma Planning Corp now owns 4,055 shares of the medical research company’s stock valued at $294,000 after buying an additional 191 shares during the period. Finally, Apollon Wealth Management LLC lifted its position in Edwards Lifesciences by 8.9% during the 1st quarter. Apollon Wealth Management LLC now owns 7,916 shares of the medical research company’s stock worth $574,000 after acquiring an additional 645 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 0.7%

Shares of NYSE EW opened at $86.17 on Friday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock’s 50 day moving average price is $78.09 and its two-hundred day moving average price is $77.65. Edwards Lifesciences Corporation has a 52-week low of $65.31 and a 52-week high of $87.21. The stock has a market capitalization of $50.00 billion, a P/E ratio of 12.40, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the business posted $0.67 earnings per share. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on EW. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Jefferies Financial Group set a $98.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Finally, Citigroup raised their target price on Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.39.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 22,970 shares of company stock worth $1,862,878 over the last ninety days. Company insiders own 0.34% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.